Medindia

X

GSK’s Cervarix may Reduce Risk of Anal Cancer in Women

by Kathy Jones on  August 23, 2011 at 7:21 PM Women Health News   - G J E 4
A new study published in the journal The Lancet Oncology suggests that the GlaxoSmithKline's vaccine for cervical cancer is also effective in reducing the risk of anal cancer among women.
 GSK’s Cervarix may Reduce Risk of Anal Cancer in Women
GSK’s Cervarix may Reduce Risk of Anal Cancer in Women
Advertisement

Researchers from the University of Missouri-Kansas City School of Medicine conducted the study to test the effectiveness of the vaccine, known as Cervarix, among more than 4,200 aged between 18 to 25 years in Costa Rica.

Advertisement
After four years, the researchers tested the participants for cervical and anal infections caused by various strains of the human papillomavirus (HPV) and found that those who were injected with Cervarix had a 76 percent lower chance of cervical cancer and a 62 percent lower risk of anal cancer compared to others.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All